A process for making epoxide intermediates
CA 2303797 A1 · Owner: The Procter & Gamble Company · Inventors: De, Biswanath; Wos, John August; Amburgey, Jack S. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been surprisingly discovered that the disadvantages of the lengthy literature procedures to synthesize 13,14-dihydro prostaglandin A E, and F , derivatives can be overcome using a novel Methyl 7-(2-hydroxy-5-(2-(2oxiranyl)ethyl)-4-(1,1,2,2tetramethyl-1-silapropoxy)cyclopentyl) heptanoate intermediate, which can be synthesized from commercially available Methyl 7-3- (R)-hydroxy-5-oxo-1-cyclopent-1-yl heptanoate. This novel intermediate can be coupled with oxygen, carbon, sulfur, and nitrogen nucleophiles in the , presence of a base or a Lewis acid in a ring-opening process to provide 13,14dihydro prostaglandin A, E, and F derivatives.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 4, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 4, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 4, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.